|
03 Jun 2019 |
Vical and Brickell Announce Merger Agreement
|
|
31 May 2019 |
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL
|
|
30 May 2019 |
Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration
|
|
30 May 2019 |
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
|
|
29 May 2019 |
Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele Announce Exclusive Worldwide License Agreement for the Treatment of MPS-I
|
|
29 May 2019 |
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
|
|
29 May 2019 |
Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty Platform
|
|
28 May 2019 |
Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss
|
|
24 May 2019 |
FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma treatment in more than 15 years In
|
|
21 May 2019 |
Evotec jump-starts biologics with acquisition of Just Biotherapeutics
|
|
21 May 2019 |
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
|
|
21 May 2019 |
CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary
|
|
21 May 2019 |
Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse
|
|
18 May 2019 |
Ligand Licenses VER250840 to Cumulus Oncology
|
|
16 May 2019 |
Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products
|
|
16 May 2019 |
HDL Therapeutics Announces Positive Data From Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia
|
|
16 May 2019 |
ASC Therapeutics Licenses Critical Technologies for Hemophilia A Gene Therapy from Expression Therapeutics
|
|
16 May 2019 |
Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune Diseases
|
|
16 May 2019 |
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
|
|
15 May 2019 |
Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
|
|
15 May 2019 |
Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases
|
|
15 May 2019 |
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
|
|
14 May 2019 |
Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
|
|
12 May 2019 |
TriSalus Life Sciences’ Pressure-Enabled Drug Delivery (PEDD) Increases Penetration and Antitumor Activity of Anti-CEA CAR-T in Mouse Model of Liver Metastases
|
|
10 May 2019 |
Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets
|
